$Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients$

Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients

Gefitinib (ZD1839, Iressa), a member of the 4-anilinoquinazoline class of compounds, has the chemical name 4-quinazolinamine, N-(3-chloro-4-flurophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]. Gefitinib often is referred to as a "specific" or "selective" inhibitor of epidermal gr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer investigation 2006-01, Vol.24 (3), p.310-317
Hauptverfasser:	Freeman, Burgess B., Daw, Najat C., Geyer, J. Russell, Furman, Wayne L., Stewart, Clinton F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - analogs & derivatives Camptothecin - therapeutic use Central Nervous System Neoplasms - drug therapy Child Clinical pharmacology Clinical Trials as Topic Drug Resistance, Neoplasm Epidermal growth factor receptor (EGFR) Gefitinib Humans pediatrics Quinazolines - pharmacokinetics Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - drug effects Receptor, Epidermal Growth Factor - metabolism ZD1839
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!